When you’re prescribed a biologic drug like Humira for rheumatoid arthritis or Crohn’s disease, you might assume your insurance will cover it. But if your doctor suggests switching to a biosimilar-a cheaper, FDA-approved version of the same drug-you could hit a wall. Not because it’s less effective. Not because it’s unsafe. But because your insurance plan treats it the same as the original, even when it costs less. In 2025, biosimilars are still stuck in the same high-cost tiers as their brand-name counterparts, and nearly every plan still requires prior authorization before you can even start treatment. This isn’t an accident. It’s a system designed to protect profits, not patients.
What Are Biosimilars, Really?
Biosimilars aren’t generics. You can’t make them by mixing chemicals in a lab like you do with pills. They come from living cells-yeast, bacteria, or mammalian cells-and are engineered to match a reference biologic drug as closely as possible. The FDA requires them to show no meaningful difference in safety, purity, or potency. The first one, Zarxio, got approved in 2015. Since then, over 70 have been approved, and about 40 are actually on the market. But even though they cost 10% to 33% less than the original, most insurance plans don’t treat them like the bargain they are.
Take Humira. It’s one of the most prescribed biologics in the U.S., costing around $5,000 per month. Eight different biosimilars have hit the market since 2023. But according to JAMA Network data from June 2024, only half of Medicare Part D plans cover even one of them. And of those that do, 99% put the biosimilar on the exact same tier as Humira. That means if you’re paying 33% coinsurance on Humira, you’re paying the same on the biosimilar-even though the biosimilar’s list price is lower. The difference? A few dollars a month. Not enough to move the needle for most patients.
Why Prior Authorization Is a Barrier, Not a Safeguard
Prior authorization is supposed to be a tool to prevent unnecessary or risky prescriptions. But for biosimilars, it’s become a gatekeeping tactic. In 2025, 98.5% of insurance plans that cover Humira also require prior authorization for its biosimilars. Not one plan has made the process easier for the cheaper option. You still need your doctor to submit medical records, prove you’ve tried other treatments, and justify why you need the drug. Approval can take 3 to 14 days. During that time, your condition can worsen.
Rheumatologists report spending 3 to 5 hours a week just filling out paperwork for prior auths. One case study from the Rheumatology Advisor showed a patient with severe arthritis waited 28 days to get approved for treatment because the plan forced a trial of a biosimilar first-even though the patient had already failed multiple other therapies. That’s not clinical care. That’s administrative delay.
And here’s the kicker: you can’t even ask your pharmacist to swap Humira for a biosimilar unless it’s labeled “interchangeable.” Only one of the eight adalimumab biosimilars has that designation-and even then, it only applies to a low-dose version rarely used in practice. So for most patients, switching isn’t a choice. It’s a bureaucratic hurdle.
Tier Placement: The Hidden Cost of Being the Same
Insurance formularies divide drugs into tiers. Tier 1 is cheap generics. Tier 4 or 5 is where biologics live. These are specialty drugs. You don’t pay a flat copay-you pay a percentage of the total cost. For Humira, that’s often 33%. That’s $1,500 a month out of pocket for many patients.
Biosimilars? Same tier. Same coinsurance. Same cost. The Drug Channels Institute found that in 2024, only 1.5% of plans placed biosimilars on a lower tier than the reference product. That’s not a mistake. That’s strategy. PBMs (pharmacy benefit managers) like Express Scripts, CVS Caremark, and OptumRx control which drugs get covered and where. And they’ve been slow to move because the original manufacturers pay them rebates to keep biosimilars off preferred lists.
But something’s changing. In 2025, Express Scripts removed Humira entirely from its commercial formularies. Not because it’s unsafe. Not because it’s ineffective. But because they want you to use a biosimilar instead. They placed multiple biosimilars on Tier 3-their preferred specialty tier-with 25% coinsurance instead of 33%. That’s a $200 monthly savings for patients. It’s not perfect, but it’s progress.
Why Insurers Are Still Holding Back
On paper, biosimilars should be a win for everyone. Patients pay less. Insurers spend less. The whole system saves money. The Congressional Budget Office estimates biosimilars could cut federal healthcare spending by $5.3 billion a year by 2030-if we let them.
But the system isn’t built for that. Biologic manufacturers like AbbVie (maker of Humira) pay billions in rebates to PBMs to keep their drugs on top-tier formularies. PBMs get paid based on the list price of drugs, not the net cost after rebates. So if you switch to a cheaper biosimilar, the PBM’s cut shrinks. That’s why, despite FDA approval and clinical equivalence, PBMs drag their feet.
The Federal Trade Commission called this out in 2023, saying these practices are anti-competitive. The Office of Inspector General agreed, noting that most Part D plans still don’t incentivize biosimilar use. Even when biosimilars are covered, they’re not promoted. No patient education. No financial push. No pharmacist counseling. It’s like they’re invisible.
What’s Actually Working?
Europe doesn’t have this problem. There, biosimilars make up over 80% of the market for drugs like Humira. Why? Because insurers actively steer patients toward them. They lower coinsurance. They waive prior auth. They let pharmacists substitute without doctor approval.
In the U.S., the few success stories are happening at the edges. Some Medicaid programs and VA hospitals have adopted aggressive biosimilar policies. One private insurer in California cut Humira use by 60% in a year by switching all new patients to a biosimilar and covering it on a lower tier. Patient satisfaction stayed high. Costs dropped by 40%.
And now, CMS is watching. After the OIG report in late 2024, Medicare started requiring plans to report how they treat biosimilars compared to brand-name biologics. For the first time, there’s data. And with data comes pressure. The Inflation Reduction Act gives CMS new power to penalize plans that discriminate against biosimilars. That’s why analysts predict biosimilar adoption will hit 40% by 2027-if regulators don’t back down.
What You Can Do
If you’re on a biologic and your doctor suggests a biosimilar:
- Ask if your plan covers it-and on what tier.
- Request a copy of your formulary. Look for the drug name and its tier.
- If it’s on the same tier, ask your doctor to appeal. Point out the cost difference and clinical equivalence.
- Call your insurer’s member services. Ask why the biosimilar isn’t on a lower tier. Record the date, rep name, and what they say.
- If you’re denied, file a formal appeal. Use the FDA’s approval data and your doctor’s letter as proof.
Some patients have won appeals by showing they’ve already paid $1,200 a month for Humira and that the biosimilar is clinically identical. It’s not easy. But it’s possible.
The Bigger Picture
This isn’t just about Humira or insulin. It’s about how the U.S. healthcare system values cost savings. We spend more on drugs than any other country. We have the science to make cheaper, equally effective alternatives. But we’ve built a system where the middlemen profit from high prices, and patients pay the price.
Biosimilars are a test. Will we let innovation lower costs? Or will we let old business models block progress? Right now, the answer is mixed. Some insurers are waking up. Others are doubling down. But the data is clear: when biosimilars get fair access, patients get better care at lower cost. And the system saves billions.
The question isn’t whether biosimilars work. They do. The question is whether we’re willing to let them.
Are biosimilars as safe as the original biologic drugs?
Yes. The FDA requires biosimilars to prove they’re highly similar to the reference product in structure, function, safety, and effectiveness. They undergo the same rigorous testing as new biologics. Thousands of patients have used biosimilars for years with no increased risk of side effects compared to the original. The FDA approved the first biosimilar in 2015, and since then, over 70 have met the same high standards.
Why don’t insurance plans put biosimilars on lower tiers?
Most plans don’t because pharmacy benefit managers (PBMs) get paid based on the list price of drugs, not the net cost after rebates. Brand-name biologic manufacturers pay PBMs large rebates to keep their drugs on preferred tiers. If a biosimilar is placed lower, the PBM loses money. So even though biosimilars cost less, PBMs have little incentive to make them cheaper for patients-unless forced to by regulation or competition.
Can my pharmacist switch my Humira to a biosimilar without my doctor’s approval?
Only if the biosimilar has an "interchangeable" designation from the FDA. Right now, only one of the eight adalimumab biosimilars has that status-and only for a low-dose version rarely used in practice. For most patients, a pharmacist can’t substitute automatically. Your doctor must specifically prescribe the biosimilar, and even then, prior authorization is often required.
How long does prior authorization for biosimilars take?
It typically takes 3 to 14 business days. Your doctor must submit medical records showing you’ve tried other treatments, your diagnosis, and why the drug is necessary. Delays can mean weeks without treatment, which is dangerous for chronic conditions like rheumatoid arthritis or Crohn’s disease. Some insurers are starting to streamline this for biosimilars, but most still treat them the same as the original drug.
What’s the difference between a biosimilar and a generic drug?
Generics are exact copies of small-molecule drugs made from chemicals. Biosimilars are made from living cells and are highly similar-but not identical-to their reference biologic. Because they’re more complex, they can’t be exact copies. But they must meet strict FDA standards proving they work the same way in the body, with no meaningful difference in safety or effectiveness. They’re not generics. They’re a different category of medicine.
Is there any progress in 2025 to improve biosimilar access?
Yes. In 2025, Express Scripts removed Humira from all its commercial formularies and placed multiple biosimilars on preferred tiers with lower coinsurance. CMS is now requiring Medicare plans to report how they treat biosimilars versus brand-name biologics. The FTC and OIG have issued warnings about anti-competitive practices. These steps are small, but they’re signs that change is coming-especially as more PBMs realize excluding originators can drive down costs.
Heather Josey
January 2, 2026 AT 23:06Biosimilars should be the default option, not the exception. I’ve seen patients delay treatment for weeks just because of prior auth hurdles-some end up in the ER because of it. The fact that insurers still treat them as equals to brand-name drugs is baffling. They’re cheaper, proven safe, and FDA-approved. Why are we still playing this game?
Doctors shouldn’t have to spend hours on paperwork just to give someone a life-changing medication. This isn’t healthcare-it’s bureaucracy with a side of greed.
Donna Peplinskie
January 4, 2026 AT 14:32I’m a rheumatology nurse in Vancouver, and I’ve watched this play out for years. In Canada, biosimilars are the standard-no prior auth, no tier games. Patients switch seamlessly, save money, and feel heard. Here in the U.S., we’re stuck in a loop where profits matter more than outcomes. It’s heartbreaking.
Why do we let middlemen dictate care? We have the science. We have the evidence. We just don’t have the will.
Alex Warden
January 5, 2026 AT 04:39This is why America’s healthcare is broken. You get a cheaper drug, and instead of celebrating, the system punishes you with red tape. PBMs? They’re just middlemen who profit off suffering. And politicians? They take their money and do nothing. Wake up, people. This isn’t about science-it’s about who’s getting paid.
Lee M
January 5, 2026 AT 05:02It’s not about access-it’s about control. The system doesn’t want you to save money. It wants you dependent. Biologics aren’t just drugs-they’re a business model built on perpetual need. Biosimilars threaten that. So they bury them under paperwork, tier games, and bureaucratic fog. This isn’t capitalism. It’s rent-seeking dressed up as medicine.
Liam George
January 5, 2026 AT 16:10Think about it: who controls the data? Who owns the algorithms that decide your tier? The same corporations that fund both sides of the political aisle. The FDA? Just a fig leaf. The real decision-makers are the PBMs and their shadowy rebate deals. And guess what? They’re working with the same banks that own the drug companies. This isn’t a flaw-it’s the design.
You think this is about healthcare? It’s about financial engineering. Biosimilars are a threat to the entire rentier system. That’s why they’re being suppressed. The truth is buried under 14-day prior auth forms and 33% coinsurance.
Bill Medley
January 6, 2026 AT 17:59Empirical evidence supports biosimilar efficacy. Regulatory standards are robust. Cost savings are measurable. Systemic inertia persists due to financial misalignment. Reform requires structural incentive realignment. Data transparency is the first step. Regulatory enforcement must follow.
Richard Thomas
January 7, 2026 AT 17:42It’s funny, isn’t it? We live in a society that worships innovation-until it threatens profit margins. We celebrate the science behind biosimilars, the precision of cellular engineering, the decades of research-but then we lock them behind a wall of rebates and paperwork. We treat them like they’re less than, even though they’re scientifically identical.
What does that say about us? That we value money more than health? That we’d rather see someone suffer for 28 days than lose a few billion in rebates? We call this progress? We call this a system?
Maybe the real question isn’t why biosimilars are blocked-it’s why we’ve accepted this as normal. Why we don’t riot in the streets. Why we just click ‘appeal’ and wait.
I used to think healthcare was broken. Now I think it’s working exactly as intended.
Paul Ong
January 9, 2026 AT 08:09My cousin switched to a biosimilar and saved $1800 a month. No side effects. No drama. Just cheaper, same results. Why is this even a debate? Someone’s making money off your pain. Fight back. Ask. Appeal. Demand. You’ve got nothing to lose but the bill.
Todd Nickel
January 10, 2026 AT 19:03One thing that’s rarely discussed is the role of formulary design in perpetuating this. PBMs don’t just set tiers-they control which drugs are even listed as alternatives. Even when a biosimilar is approved, if it’s not on the formulary at all, the patient has no pathway. And formularies are opaque. Patients can’t access them easily. Doctors are often unaware of what’s covered until they’re mid-prior auth. This isn’t negligence-it’s structural obscurity designed to maintain the status quo.
Plus, there’s the psychological barrier: patients assume ‘brand-name’ means ‘better.’ Even when told otherwise, the stigma lingers. Insurance companies don’t correct this. They don’t educate. They don’t promote. They let the myth persist because it keeps the revenue flowing.
The VA model proves this isn’t inevitable. When you remove the middlemen and prioritize clinical outcomes, adoption skyrockets. The fact that it’s only happening in pockets tells us the problem isn’t technical-it’s political.
Layla Anna
January 12, 2026 AT 02:15My mom got switched to a biosimilar last year and cried because she thought they were ‘fake’ meds 😭
She’s fine now-better even, no more stomach issues from the old one-and saved $1500/month. We had to fight the insurance for 3 weeks though. I wish someone had told her earlier that it’s not a downgrade. It’s an upgrade. 💙
Why don’t we have a simple ‘Biosimilar = Same Drug, Lower Price’ sticker on the bottle? Like a nutrition label? People need to know this isn’t a gamble.
Olukayode Oguntulu
January 12, 2026 AT 07:13Let’s be honest-this is the inevitable collapse of Western pharmaceutical hegemony. The U.S. has turned medicine into a luxury good, while the rest of the world-especially emerging economies-see biosimilars as the logical evolution of equitable care. You’re clinging to a 20th-century profit model while the 21st century is already here, with AI-driven manufacturing and decentralized biologics production. Your PBMs? They’re the last gasp of rentier capitalism. The future belongs to those who prioritize access over extraction.
jaspreet sandhu
January 13, 2026 AT 00:45You guys are all missing the point. Biosimilars are just a distraction. The real problem is that no one in America gets real healthcare. You think fixing tier placement will fix anything? Nah. The whole system is rigged. Even if biosimilars were free, you’d still need to pay $200 just to see a doctor. The insurance companies don’t care about drugs-they care about controlling every single step. You’re arguing over crumbs while the whole table is stolen. Stop focusing on biosimilars. Start fighting the whole machine.